Perfil
Mel L.
Billingsley is currently the President & Chief Executive Officer at Life Sciences Greenhouse of Central Pennsylvania since 2002.
He is also a Professor at The Pennsylvania State University.
He completed his undergraduate degree from the University of Pittsburgh in 1974 and received his doctorate degree from George Washington University.
Cargos activos de Mel L. Billingsley
| Empresas | Cargo | Inicio |
|---|---|---|
Life Sciences Greenhouse of Central Pennsylvania
Life Sciences Greenhouse of Central Pennsylvania Investment ManagersFinance LSGPA invests in companies located in the United States. The firm focuses on drug design, drug delivery systems, biomedical devices, biopharmaceutical manufacturing innovation, drug assay/detection/screening systems and bio nanotechnology. It participates in early-stage capital transactions. | Director Ejecutivo | 01/01/2002 |
The Pennsylvania State University
The Pennsylvania State University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Formación de Mel L. Billingsley.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 4 |
|---|---|
University of Pittsburgh
University of Pittsburgh Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
George Washington University
George Washington University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Pennsylvania State University
The Pennsylvania State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Life Sciences Greenhouse of Central Pennsylvania
Life Sciences Greenhouse of Central Pennsylvania Investment ManagersFinance LSGPA invests in companies located in the United States. The firm focuses on drug design, drug delivery systems, biomedical devices, biopharmaceutical manufacturing innovation, drug assay/detection/screening systems and bio nanotechnology. It participates in early-stage capital transactions. | Finance |
- Bolsa de valores
- Insiders
- Mel L. Billingsley
















